ArticleFrontiers in cellular and infection microbiology2024
Rising challenges in periprosthetic joint infections: a focus on rare pathogens and their clinical implications.
Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The proportion of chronic periprosthetic joint infection patients withJournal of bone and joint infection · 2026Article
- Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Comprehensive analysis of culture-negative periprosthetic joint infection with metagenomic next-generation sequencing.Frontiers in cellular and infection microbiology · 2025Article
- Immunomodulatory factors CRP/albumin ratio and NLR predict post-spinal surgery infection.Frontiers in surgery · 2025Article
- Impact of Antibiotic Exposure Duration on Pathogen Detection in Periprosthetic Joint Infection.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The study aimed to evaluate differences in clinical characteristics and treatment outcomes of periprosthetic joint infection (PJI) attributed to rare versus common pathogens. Methods: Data on PJI patients who underwent hip or knee arthroplasty at our center from April 2013 to December 2022 were retrospectively collected. Among the 219 enrolled patients, we compared 32 cases of PJI caused by rare pathogens with 187 controls of PJI caused by common pathogens, analyzing demographic information, clinical characteristics, and treatment outcomes. Results: In demographic data, the Charlson comorbidity index and preoperative invasive procedures were identified as risk factors for rare pathogen PJI. Clinically, the rare pathogen cohort exhibited a significantly higher rate of sinus tract formation compared to those with common bacteria PJI. In terms of laboratory findings, the mean serum C-reactive protein (CRP) was significantly lower in the rare pathogen group. This cohort also had a significantly lower culture positivity rate and a higher rate of polymicrobial co-infections. The median hospital stay was statistically longer for rare pathogen PJI cases than for those with common bacteria PJI. Furthermore, the rare pathogen group required longer antibiotic treatments and had higher rates of antibiotic-related adverse events, although reinfection rates did not significantly differ. Conclusion: PJI caused by rare pathogens exhibits distinct clinical presentations. With advances in diagnostic techniques such as metagenomic next-generation sequencing (mNGS), optimized culture methods, and an interdisciplinary approach facilitating early targeted treatment, rare pathogen PJIs may achieve outcomes comparable to those of typical cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.